Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast Cancer

NCT00548899 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Nexavar (Sorafenib)

Sponsor

GBG Forschungs GmbH

Collaborators

[object Object]